BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
24.35 EUR
-0.05 (-0.2%)
Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 29 industry peers in the Health Care Providers & Services industry. While BLC is still in line with the averages on profitability rating, there are concerns on its financial health. BLC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.08%, BLC is doing worse than 79.31% of the companies in the same industry.
Looking at the Return On Equity, with a value of 0.73%, BLC is doing worse than 75.86% of the companies in the same industry.
BLC's Return On Invested Capital of 6.40% is fine compared to the rest of the industry. BLC outperforms 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.67%.
The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.40%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROIC | 6.4% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
BLC has a worse Profit Margin (0.11%) than 79.31% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
BLC has a better Operating Margin (8.17%) than 65.52% of its industry peers.
BLC's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 67.80%, BLC is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BLC is still creating some value.
BLC has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
BLC has an Altman-Z score of 1.39. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
BLC has a worse Altman-Z score (1.39) than 65.52% of its industry peers.
The Debt to FCF ratio of BLC is 12.90, which is on the high side as it means it would take BLC, 12.90 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 12.90, BLC is not doing good in the industry: 65.52% of the companies in the same industry are doing better.
BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 5.29, BLC is not doing good in the industry: 89.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.39 |
ROIC/WACC1.27
WACC5.02%
2.3 Liquidity
A Current Ratio of 1.38 indicates that BLC should not have too much problems paying its short term obligations.
BLC's Current ratio of 1.38 is fine compared to the rest of the industry. BLC outperforms 75.86% of its industry peers.
BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.18, BLC is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.35%.
BLC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.12% yearly.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.18% yearly.
The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BLC is valuated quite expensively with a Price/Earnings ratio of 347.86.
Based on the Price/Earnings ratio, BLC is valued a bit more expensive than the industry average as 79.31% of the companies are valued more cheaply.
The average S&P500 Price/Earnings ratio is at 26.59. BLC is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 9.74, the valuation of BLC can be described as reasonable.
Based on the Price/Forward Earnings ratio, BLC is valued cheaper than 89.66% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, BLC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 347.86 | ||
| Fwd PE | 9.74 |
4.2 Price Multiples
89.66% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than the industry average as 79.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.63 | ||
| EV/EBITDA | 5.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)18.32
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (12/10/2025, 7:00:00 PM)
24.35
-0.05 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap179.46M
Revenue(TTM)491.18M
Net Income(TTM)528.00K
Analysts83.33
Price Target36.72 (50.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.5%
EPS NY rev (3m)-16.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 347.86 | ||
| Fwd PE | 9.74 | ||
| P/S | 0.37 | ||
| P/FCF | 5.63 | ||
| P/OCF | 1.95 | ||
| P/B | 2.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.61 |
EPS(TTM)0.07
EY0.29%
EPS(NY)2.5
Fwd EY10.27%
FCF(TTM)4.32
FCFY17.76%
OCF(TTM)12.48
OCFY51.24%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)18.32
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROCE | 8.71% | ||
| ROIC | 6.4% | ||
| ROICexc | 6.78% | ||
| ROICexgc | 12.12% | ||
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.25% | ||
| Profit Quality | 6036.93% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.39 |
F-Score8
WACC5.02%
ROIC/WACC1.27
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y18.25%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 347.86 and the Price/Book (PB) ratio is 2.49.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.77%.